Rising Demand for Gene Therapies Drives Growth in Viral Vector Production Market
Author : kaustubh Ravan | Published On : 05 Jun 2026
The global viral vector production industry was valued at US$ 16.7 billion in 2022. The market is anticipated to expand at a CAGR of 4.4% from 2023 to 2031 and is projected to reach more than US$ 17.3 billion by 2031. Increasing demand for gene therapy, vaccine development, and advanced biologic treatments is driving market growth globally. Viral vectors play a critical role in delivering genetic material into cells and are widely used in gene therapies, cell therapies, and vaccine manufacturing, particularly for complex diseases such as cancer, genetic disorders, and infectious diseases.
Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85250
The growing number of clinical trials for gene therapies and rising approvals of cell-based therapies are significantly boosting demand for viral vector manufacturing capabilities. Viral vector production technologies are increasingly being adopted by pharmaceutical and biotechnology companies to support the commercialization of precision medicine and personalized treatment solutions. Additionally, rising investments in biopharmaceutical manufacturing infrastructure are expected to support market expansion.
Technological advancements in vector engineering, scalable bioprocessing, and manufacturing optimization are transforming the viral vector production market landscape. Manufacturers are increasingly focusing on improving vector yield, purity, scalability, and cost-effectiveness to meet growing therapeutic demand. Furthermore, increasing collaborations between contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies are accelerating market development during the forecast period.
Key Findings of the Market Report
● Increasing adoption of gene and cell therapies is expected to drive demand for viral vector production.
● Adeno-associated viral vectors (AAV) are anticipated to account for a major market share due to growing gene therapy applications.
● Pharmaceutical and biotechnology companies are increasingly investing in scalable vector manufacturing technologies.
● Rising number of clinical trials for advanced therapeutics is creating lucrative opportunities for market growth.
● Contract manufacturing organizations are playing a critical role in expanding production capacity.
Global Viral Vector Production Market: Growth Drivers
· Rising prevalence of genetic disorders, cancer, and rare diseases is significantly boosting demand for gene therapy solutions.
· Increasing investments in cell & gene therapy research and biopharmaceutical manufacturing infrastructure are driving market growth.
· Growing approvals and commercialization of gene-based therapies are accelerating adoption of viral vector production technologies.
· Technological advancements in bioprocessing, vector engineering, and manufacturing scalability are improving production efficiency.
· Rising collaborations between biotechnology firms and CDMOs are supporting long-term market expansion.
Global Viral Vector Production Market: Regional Landscape
· North America is expected to witness strong market growth owing to increasing investments in biotechnology research, presence of leading biopharmaceutical companies, and rising clinical trials for gene therapies.
· Europe is anticipated to experience steady growth due to strong regulatory support and increasing focus on advanced therapeutic medicinal products (ATMPs).
· Asia Pacific is projected to emerge as a lucrative market owing to expanding biotechnology infrastructure and increasing investments in precision medicine.
Global Viral Vector Production Market: Key Players
Major market participants are focusing on production expansion, strategic collaborations, technological innovation, and manufacturing optimization to strengthen their market position.
● Thermo Fisher Scientific Inc.
● FUJIFILM Diosynth Biotechnologies
● Lonza Group AG
● Catalent, Inc.
● Charles River Laboratories International, Inc.
● Oxford Biomedica plc
● Merck KGaA
● Sartorius AG
● Cobra Biologics
● Takara Bio Inc.
Key Developments
● Companies are increasingly expanding viral vector manufacturing facilities to meet rising demand for gene therapy commercialization.
● Growing partnerships between biotechnology firms and CDMOs are accelerating innovation in scalable vector production technologies.
Global Viral Vector Production Market: Segmentation
By Vector Type
● Adenoviral Vectors
● Adeno-associated Viral (AAV) Vectors
● Lentiviral Vectors
● Retroviral Vectors
● Others
By Workflow
● Upstream Processing
● Downstream Processing
By Application
● Gene Therapy
● Vaccinology
● Cell Therapy
● Research Applications
By End-user
● Pharmaceutical & Biotechnology Companies
● Research Institutes
● Contract Manufacturing Organizations (CMOs)
● Others
By Region
● North America
● Latin America
● Europe
● Asia Pacific
● Middle East & Africa
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=85250<ype=S
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
